Table of Content

1. Biosimiliars: A New Era in Cancer Therapeutics
1.1 Overview to Cancer Biosimilars
1.2 History of Biosimilars


2. Development of Biosimilars


3. Need of Cancer Biosimilars in US


4. US Comparative Price Analysis of Marketed Cancer Bosimilars
4.1 Avastin
4.2 Herceptin
4.3 Rituximab


5. US Reimbursement Scenario for Cancer Biosimilars
5.1 Current Scenario
5.2 Future Potential of Reimbursement Scenario


6. US Cancer Biosimilar Market Overview
6.1 Current Biosimilar Market Scenario
6.2 US Cancer Biosimilar Market
6.3 Off Going Patents: Biosimilar Opportunity Ahead


7. US Cancer Biosimilar Market by Product
7.1 Rituximab
7.2 Herceptin
7.3 Avastin



8. US Potential Cancer Biosimilars Market Opportunity By Popular Drugs Patent Expiry
8.1 Erbitux Biosimilar
8.2 Vectibix Biosimilar
8.3 Yervoy Biosimilar
8.4 Trodelvy Biosimilar
8.5 Perjeta Biosimilar
8.6 Gazyva Biosimilar
8.7 Darzlex Biosimilar
8.8 Xgeva Biosimilar
8.9 Cyramza Biosimilar
8.10 Kadcyla Biosimilar
8.11 Opdivo Biosimilar
8.12 Tagraxofusp Biosimilar
8.13 Tecentriq Biosimilar
8.14 Keytruda Biosimilar
8.15 Imfinzi Biosimilar


9. US Biosimilar Clinical Pipeline By Company Indication & Phase
9.1 Preclinical
9.2 Phase-I
9.3 Phase-III
9.4 Preregistration
9.5 Registered


10. US Marketed Biosimilar Clinical Insight


11. US Cancer Biosimilar Market vs. Global Cancer Biosimilar Market
11.1 Europe Cancer Biosimilar Market
11.2 Japan Cancer Biosimilar Market
11.3 India Cancer Biosimilar Market
11.4 China Cancer Biosimilar Market
11.5 South Korea Cancer Biosimilar Market


12. US Biosimilar vs Generic Cancer Drug Market


13. US Cancer Biosimilar Market Dynamics
13.1 US Cancer Biosimilar Market Drivers
13.2 Barriers to US Biosimilar Market


14. US Cancer Biosimilar Future Outlook


15. Competitive Landscape
15.1 Amgen
15.2 AstraZencea
15.3 Biogen
15.4 Coherus Bioscience
15.5 Eli Lilly
15.6 F. Hoffmann-La Roche & Co.
15.7 Merck
15.8 Mylan Pharmaceuticals
15.9 Pfizer
15.10 Teva Pharmaceutical